ClinicalTrials.gg
RecruitingNCT07219030Updated Sep 15, 2026

A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants

A Phase 1 interventional study of Emraclidine and Placebo in Healthy Volunteer, sponsored by AbbVie. Recruiting at 5 sites in United States. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Study summary

This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-1231
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Body weight > 45 kg at the time of screening and upon initial confinement.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead .

Exclusion criteria

Exclusion Criteria:

  • History of any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, genitourinary, immunological, hematologic, neurological or psychiatric disease or disorder, or any other uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • Evidence of dysplasia or history of (including lymphoma and leukemia) other than successfully treated non- cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Emraclidine or Placebo- Group 1

    Participants will receive oral doses of emraclidine or placebo for 10 days or 17 days

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Emraclidine or Placebo- Group 2

    Participants will receive oral doses of emraclidine or placebo for 10 days or 17 days

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Emraclidine or Placebo- Group 3

    Participants will receive oral doses of emraclidine or placebo for 10 days or 17 days.

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Emraclidine or Placebo- Group 4

    Participants will receive oral doses of emraclidine or placebo for 10 days or 17 days.

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Emraclidine or Placebo- Group 5

    Participants will receive oral doses of emraclidine or placebo for 10 days or 17 days.

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Emraclidine or Placebo- Group 6

    Participants will receive oral doses of emraclidine or placebo for 10 days or 17 days.

    Drug: Emraclidine · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 50 days

  2. Number of Participants with Clinical Significant Change From Baseline in Vital Sign Measurements

    Number of participants with clinical significant change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

    Time frame: Up to approximately 20 days

  3. Number of Participants with Clinical Significant Change from Baseline in Electrocardiogram (ECG)

    12-lead resting ECG will be recorded.

    Time frame: Up to approximately 20 days

  4. Number of Participants with Clinical Significant Change in Physical Examinations

    Number of participants with clinical significant change in physical examinations will be assessed.

    Time frame: Up to approximately 20 days

  5. Number of Participants with Clinical Significant Change in Clinical Laboratory Test Results Like Hematology will be Assessed

    Number of participants with clinical significant change in clinical laboratory test results will be assessed.

    Time frame: Up to approximately 20 days

  6. Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

    Time frame: Up to approximately 20 days

  7. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)

    AIMS assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. The first 10 items are rated on a none (0) to severe (4) scale. There are an additional 2 items on dental status that are answered yes or no.

    Time frame: Up to approximately 20 days

  8. Change From Baseline in Barnes Akathisia Rating Scale (BARS)

    BARS is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia (each on a 4-point scale from normal \[0\] to severe \[3\]). In addition, there is a global severity for akathisia rated on a 6-point scale (absent \[0\] to severe akathisia \[5\]).

    Time frame: Up to approximately 20 days

  9. Change From Baseline in Simpson-Angus Scale (SAS)

    SAS is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Each item ranges from 0 (normal) to 4 (extreme symptoms). The scale consists of 1 item measuring gait (hypokinesia), 6 items measuring rigidity, and 3 items measuring glabella tap, tremor, and salivation, respectively.

    Time frame: Up to approximately 20 days

  10. Maximum Observed Plasma Concentration (Cmax) of Emraclidine

    Cmax of Emraclidine

    Time frame: Up to approximately 20 days

  11. Maximum Observed Plasma Concentration (Cmax) of Metabolite (CV-0000364)

    Cmax of Metabolite (CV-0000364)

    Time frame: Up to approximately 20 days

  12. Time to Cmax (Tmax) of Emraclidine

    Tmax of Emraclidine

    Time frame: Up to approximately 20 days

  13. Time to Cmax (Tmax) of Metabolite (CV-0000364)

    Tmax of Metabolite (CV-000036)

    Time frame: Up to approximately 20 days

  14. Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) of Emraclidine

    AUCt of Emraclidine

    Time frame: Up to approximately 20 days

  15. Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) Metabolite (CV-000036)

    AUCt of Metabolite (CV-000036)

    Time frame: Up to approximately 20 days

  16. Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Emraclidine

    AUCtau of Emraclidine

    Time frame: Up to approximately 20 days

  17. Minimum plasma concentration (Cmin) of Emraclidine

    Cmin of Emraclidine

    Time frame: Up to approximately 20 days

  18. Minimum plasma concentration (Cmin) of Metabolite (CV-0000364)

    Cmin of Metabolite (CV-0000364)

    Time frame: Up to approximately 20 days

  19. Average plasma concentration (Cavg) of Emraclidine

    Cavg of Emraclidine

    Time frame: Up to approximately 20 days

  20. Average plasma concentration (Cavg) of Metabolite (CV-0000364)

    Cavg of Metabolite (CV-0000364)

    Time frame: Up to approximately 20 days

  21. Metabolite to Parent Ratio (MRCmax) of Emraclidine

    MRCmax of Emraclidine calculated from Cmax

    Time frame: Up to approximately 20 days

  22. Metabolite to Parent Ratio (MRCmax) of Metabolite (CV-0000364)

    MRCmax of Metabolite (CV-0000364) calculated from Cmax

    Time frame: Up to approximately 20 days

  23. Metabolite to Parent Ratio (MRAUCtau) of Emraclidine

    MRAUCtau of Emraclidine based on AUCtau

    Time frame: Up to approximately 20 days

  24. Metabolite to Parent Ratio (MRAUCtau) of Metabolite (CV-000036)

    MRAUCtau of Metabolite (CV-000036) based on AUCtau

    Time frame: Up to approximately 20 days

  25. Terminal Phase Elimination Half-Life (t1/2) of Emraclidine

    Terminal phase elimination half-life of Emraclidine

    Time frame: Up to approximately 20 days

  26. Terminal Phase Elimination Half-Life (t1/2) of Metabolite (CV-000036)

    Terminal phase elimination half-life of Metabolite (CV-000036)

    Time frame: Up to approximately 20 days

  27. Apparent terminal phase elimination constant (β) of Emraclidine

    β of Emraclidine

    Time frame: Up to approximately 20 days

  28. Apparent terminal phase elimination constant (β) of Metabolite (CV-0000364)

    β of Metabolite (CV-0000364)

    Time frame: Up to approximately 20 days

  29. Peak-to-trough ratio (PTR) of Emraclidine

    PTR of Emraclidine

    Time frame: Up to approximately 20 days

  30. Peak-to-trough ratio (PTR) of Metabolite (CV-000036)

    PTR of Metabolite (CV-000036)

    Time frame: Up to approximately 20 days

  31. Accumulation ratio for Cmax (RacCmax) of Emraclidine

    RacCmax of Emraclidine

    Time frame: Up to approximately 20 days

  32. Accumulation ratio for Cmax (RacCmax) of Metabolite (CV-0000364)

    RacCmax of Metabolite (CV-0000364)

    Time frame: Up to approximately 20 days

  33. Accumulation ratio for AUCtau (RacAUCtau) of Emraclidine

    RacAUCtau of Emraclidine

    Time frame: Up to approximately 20 days

  34. Accumulation ratio for AUCtau (RacAUCtau) of Metabolite (CV-0000364)

    RacAUCtau of Metabolite (CV-0000364)

    Time frame: Up to approximately 20 days

  35. Apparent Clearance of Drug from Plasma (CL/F) of Emraclidine

    CL/F of Emraclidine

    Time frame: Up to approximately 20 days

  36. Apparent Volume of Distribution DuringTerminal Phase (Vz/F) of Emraclidine

    Vz/F of Emraclidine

    Time frame: Up to approximately 20 days

  37. Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Metabolite (CV-0000364)

    AUCtau of Metabolite (CV-0000364)

    Time frame: Up to approximately 20 days

07

Study locations

4 of 5 sites recruiting
  • Altasciences Clinical Los Angeles /ID# 276854
    Cypress, California 90630, United States
    Completed

    Not enrolling at this site.

  • K2 Medical Research, LLC /ID# 276636
    Maitland, Florida 32751, United States
    Recruiting
  • Clinical Pharmacology Of Miami /ID# 276856
    Miami, Florida 33172, United States
    Recruiting
    • Site Coordinator · Contact786-493-9466
  • Acpru /Id# 276996
    Grayslake, Illinois 60030, United States
    Recruiting
    • Site Coordinator · Contact847-935-4400
  • Hassman Research Institute Marlton Site /ID# 276876
    Marlton, New Jersey 08053, United States
    Recruiting
    • Site Coordinator · Contact888-437-4104
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Oct 21, 2025
StartActual
Oct 8, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219030
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Oct 8, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 15, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion